ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma

Steven I. Park, Thomas C. Shea, Oludamilola Olajide, Nishitha M. Reddy, Lihua E. Budde, Nilanjan Ghosh, Allison M. Deal, Jeanne F. Noe, Stephen M. Ansell

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment-related complications. New treatment paradigms are needed to reduce the use of radiation therapy (RT) as well as conventional chemotherapy drugs while improving upon current standard-of-care survival outcomes. In this phase 2 multicenter study, patients with non-bulky limited-stage HL received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by brentuximab vedotin (BV) consolidation. Forty-one patients were enrolled, and patient characteristics included median age of 29 years (range, 19 to 67 years), 58% were female, 45% had unfavorable disease, and 98% had stage II disease. Based on positron emission tomography (PET)-based risk stratification, patients received 2 to 6 cycles of ABVD followed by 6 cycles of BV. After ABVD followed by BV, 95% of evaluable patients (37 out of 39; 95% confidence interval [CI], 83%-99%) achieved PET-negative status. In the intent-to-treat patient population, the estimated 3-year progression-free survival (PFS) rate was 92%, and the overall survival (OS) rate was 97%, with a median follow-up of 47 months. All 37 patients who achieved negative PET status after BV consolidation effectively avoided RT and remain in remission with estimated 3-year PFS and OS rates of 100%. In conclusion, BV demonstrates encouraging clinical activity when it follows ABVD therapy in limited-stage HL. Early incorporation of BV may reduce the use of RT as well as conventional chemotherapy drugs while achieving favorable survival outcomes in risk-stratified patients with non-bulky limited-stage HL.

Original languageEnglish (US)
Pages (from-to)2548-2555
Number of pages8
JournalBlood Advances
Issue number11
StatePublished - Jun 9 2020

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this